Back to discover
Drug

Glimepiride

In clinical development
ClassSulfonylurea receptor 1, Kir6.2 blockerEmerging researchLate-stage development
Also known as Amaryl, Avandaryl, Duetact, Glimepirida+2 more

Amaryl, Avandaryl, Duetact, Glimepirida, Glimépiride, Glimepiridum.

RxNorm25789ChEMBLCHEMBL1481ATCA10BB12UNII6KY687524K
1
Research papers
3
Active clinical trials
2
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Transforming Hypertension Treatment in Nigeria Using a Type II Hybrid, Interrupted Time Series Design - Aim 3

Clinical trial2026-05-15Results expected Q2 2029 · ClinicalTrials.gov

A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled With Metformin and Sitagliptin

Clinical trial2026-01-26Results expected Q3 2027 · ClinicalTrials.gov

Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Advanced Type 2 Diabetes

Clinical trial2025-12-31Primary completion · ClinicalTrials.gov

Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial.

Clinical trial2025-12-17Results expected Q4 2030 · ClinicalTrials.gov

Effect of Vildagliptin Versus Glimepiride on Copeptin and Fetuin-A in Type 2 Diabetic Patients

Clinical trial2024-12-01Completed · ClinicalTrials.gov

A Relative Bioavailability Study of Glimepiride 4 mg Tablets Under Non-Fasting Conditions

Clinical trial2024-08-20Results posted · ClinicalTrials.gov

A Relative Bioavailability Study of Glimepiride 4 mg Tablets Under Fasting Conditions

Clinical trial2024-08-19Results posted · ClinicalTrials.gov

Comparison in Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes Uncontrolled With Metformin

Clinical trial2023-10-31Primary completion · ClinicalTrials.gov

The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes

Clinical trial2023-10-31Primary completion · ClinicalTrials.gov

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

Clinical trial2023-07-12Results posted · ClinicalTrials.gov

A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes

Clinical trial2022-06-07Results posted · ClinicalTrials.gov

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

Research2007-06-26Diabetes, obesity & metabolism

Evidence confidence

1 claim

How strongly the incorporated evidence supports specific clinical claims about this treatment. A confidence figure is a current summary of evidence strength, not a permanent verdict.

Improves HbA1c in type 2 diabetes
68%Moderate confidence
Uncertainty ±4%Evidence coverage: HighUpdated 31 December 2025

Evidence is mixed — 23 supporting evidence families · 4 well-powered no-effect results

Confidence is moderated by well-powered no-effect evidence, despite broad trial support.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Glimepiride
Aliases & brands
AmarylAvandarylDuetactGlimepiridaGlimépirideGlimepiridum
RxNorm CUI
25789
ChEMBL ID
CHEMBL1481
ATC codes
A10BB12
UNII
6KY687524K
Primary mechanism
Sulfonylurea receptor 1, Kir6.2 blocker

Pharmacology & targets

2 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

ATP-sensitive inward rectifier potassium channel 11
KCNJ11 · Q14654
BLOCKERSulfonylurea receptor 1, Kir6.2 blocker
ATP-binding cassette sub-family C member 8
ABCC8 · Q09428
BLOCKERSulfonylurea receptor 1, Kir6.2 blocker

Clinical trials

159 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
159
registered trials across all phases
LATEST COMPLETION 2024
3
Active studies
3
Recruiting
135
Late-stage (III+)
117
Completed
39
Discontinued
PHASE DISTRIBUTIONn = 159
Phase 115Phase 29Phase 2 / 32Phase 367Phase 450Phase N / A16

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled With Metformin and Sitagliptin

Not yet recruitingPH IVChong Kun Dang Pharmaceuticaln=2002027

Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Advanced Type 2 Diabetes

Unknown statusPH IVYonsei Universityn=922025

The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes

Unknown statusPH IVPeking University People's Hospitaln=1922024

Comparison in Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes Uncontrolled With Metformin

Unknown statusPH IVSeoul National University Bundang Hospitaln=802023

Comparison of the Effect of Fenofibrate Versus Curcumin in Type 2 Diabetic Patients Treated With Glimepiride

CompletedPH IVRehab Weridan=602021

Recent completions

Trials that read out recently, adding to the completed evidence base.

Effect of Vildagliptin Versus Glimepiride on Copeptin and Fetuin-A in Type 2 Diabetic Patients

CompletedN/ADamanhour Universityn=702024

Comparison of the Effect of Fenofibrate Versus Curcumin in Type 2 Diabetic Patients Treated With Glimepiride

CompletedPH IVRehab Weridan=602021

Comparative Effects of Empagliflozin Versus Glimepiride After 26-weeks of Treatment Add on Metformin on Myocardial Metabolic Rate of Glucose Estimated Through 18FDG-PET in Patients With Type 2 Diabetes

CompletedPH IVUniversity of Catanzaron=262021

Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver

CompletedPH IVKanazawa Universityn=402021

Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects

CompletedN/APT Harsen Laboratoriesn=342021

The Effect of Omega 3 Fatty Acids on Blood Glucose, Lipids Profile, Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride

CompletedN/ADamanhour Universityn=702020

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Journals, researchers & institutions
Top journals
  • Diabetes, obesity & metabolism1
Leading researchers
  • Fanurik D1
  • Hermansen K1
  • Khatami H1
  • Kipnes M1
  • Luo E1
  • Stein P1
Leading institutions
free-text, unnormalised
  • Aarhus University Hospital1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Metformin

Studied across 2 of the same disease areas as Glimepiride in the shared literature.

2 shared diseases1 shared paper
Sitagliptin Phosphate

Studied across 2 of the same disease areas as Glimepiride in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials